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The cancer microenvironment may be conceptually regarded as a pitch where the main
players are resident and non-resident cellular components, each covering a defined role
and interconnected by a complex network of soluble mediators. The crosstalk between
these cells and the tumor cells within this environment crucially determines the fate of
tumor progression. Immune cells that infiltrate the tumor bed are transported there by
blood circulation and exert a variety of effects, either counteracting or favoring tumor out-
growth. Here, we review and discuss the multiple populations composing the tumor bed,
with special focus on immune cells subsets that positively or negatively dictate neoplas-
tic progression. In this scenario, the contribution of cancer stem cells within the tumor
microenvironment will also be discussed. Finally, we illustrate recent advances on new
integrated approaches to investigate the tumor microenvironment in vitro.
Keywords: tumor microenvironment, dendritic cells, macrophages, myeloid-derived suppressor cells, NK cells,
T lymphocytes, cancer stem cells, solid tumors
THE TUMOR MICROENVIRONMENT: RESIDENT AND
NON-RESIDENT POPULATIONS
Similarly to the majority of normal tissues, solid tumors are com-
posed by two distinct compartments, the parenchyma and the
stroma. The parenchyma is representative of cancer cells them-
selves, whereas all non-malignant cells and the other connective
tissue elements belong to the stromal compartment (Dvorak et al.,
2011). The stroma is a very heterogeneous milieu including var-
ious cell types and adhesion molecules, both contributing to the
functional activity and structural support of the tumor microen-
vironment itself. Thus, the stromal and parenchymal regions may
often be undistinguishable. For this reason, we can conveniently
subdivide the cancer microenvironment into non-resident and
resident components (Table 1).
Through this definition the resident component comprises cell
populations and structural factors stably resident within the milieu
of the stroma. In particular, endothelial cells and pericytes are res-
ident cellular components surrounding and composing the blood
vessels. Pericytes are structural cell components of blood vessels
whose importance has been recently defined relatively to the can-
cer environment. Pericytes are commonly present in several organs
and multicomponent cell structures (Fernandez-Klett et al., 2012;
Iwasaki et al., 2012; Hellerbrand, 2013; Ren et al., 2013). Of interest,
a functional role for these structures has been recently reported in
the activation of innate immunity (Stark et al., 2013). In addition,
pericytes can also display a functional property in cancer progres-
sion. This was shown in a study employing a transgenic mouse
model expressing the viral thymidine kinase (tk) under control
of the NG2 promoter (NG2-tk mice) and transplanted with 4T1
breast cancer cells. In this work, Cooke et al. (2012) reported that
treatment with Ganciclovir induced depletion of pericytic struc-
tures in tumors from NG2-tk mice but not in those from control
mice, that was associated with markedly increased breast can-
cer progression and metastatic potential in mutant animals. The
mesenchyma is another macrostructure belonging to the resident
components, and is composed by several cellular types constantly
present in this environment, such as fibroblasts, mesenchymal
cells, and cancer stem cells (CSC). Other structural components
such as adhesion molecules, cytokines, chemokines, and other bio-
logical compounds of functional relevance are all essential and
confer to mesenchyma a time- and space-dependent functional
role for the expansion of the tumor mass.
Belonging to the non-resident constituent are different
immune cell populations with the ability to infiltrate the cancer
microenvironment by extravasation or through the help of blood
vessels. In this scenario, resident and non-resident elements of the
tumor microenvironment constantly interact and together repre-
sent a new forming, independent organ within the body (Table 1)
(Dvorak et al., 2011). Hence, resident cancer cells produce selected
chemokines that will set the composition of the infiltrating, non-
resident fraction through the recruitment of leukocytes expressing
specific chemokine receptors (reviewed in Toh et al., 2012; Viola
et al., 2012). An example of cancer microenvironment compo-
sition is depicted in Figure 1 (Mattei et al., 2012), illustrating a
section of a B16.F10 melanoma tumor grown in C57/Bl6 syn-
geneic mice. Hematoxylin/Eosin staining evidences the presence
of infiltrating leukocytes surrounding the tumor mass (Figure 1A)
as well as blood vessels and other structural components inside the
tumor milieu (Figure 1B).
Recent studies indicate a role for microRNAs (miRs),
pleiotropic regulators of gene expression, as critical components
of the tumor microenvironment. Deregulation of miR expression
at the tumor site has been reported to affect tumor progression
and metastasis (Li et al., 2013). It has been evidenced that can-
cer cells are endowed with the ability to produce some classes
of miRs, such as miR21 and miR29a (Fabbri, 2012; Fabbri et al.,
2012). When produced by cancer cells, these little, non-coding,
sequences of RNA were internalized by exosomes and secreted
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outside the cell, diffusing in the tumor milieu. By exploiting
their expression of TLRs, such as TLR-7 (in mice) and TLR-8
(in humans), neighboring immune cells promptly captured these
RNA sequences and internalized them via the exosomes. At this
point, miR21 and miR29a exert their action by altering the tran-
scriptional machinery of the cells (Fabbri, 2012; Fabbri et al.,
2012). Of note, all immune cells expressing TLRs, such as DCs, are
potentially exposed to this scenario. Therefore, miRs can be seen
as integrated components of the tumor bed, acting as paracrine
biological factors that contribute to the crosstalk between cancer
and immune cells, together with the cytokine network generated
therein, and orchestrating the fate of cancer progression.
IMMUNE CELLS INFILTRATING THE TUMOR
MICROENVIRONMENT: ROLE IN CANCER PROGRESSION
Immune cell infiltration within a solid tumor is a naturally occur-
ring event, when cells belonging to immune system enter within
the tumor microenvironment by means of tumor-forming blood
vessels and/or extravasation. This event can sometimes lead to
blocking of cancer progression and thus limit or even prevent
the generation of metastasis (Vesely et al., 2011). In general, this
occurs when tumor progression is at early stages as a result of
host immunosurveillance. At this point, if the organism is able to
generate a prompt tumor-specific immune response, cancer pro-
gression is contrasted by immune forces and sometimes inhibited.
In many cases, unfortunately, the host is unable to generate an
effector immune response toward the tumor, due to the ability
of the tumor to activate immunosuppressive mechanisms that
FIGURE 1 | Composition of the tumor microenvironment from a
mouse melanoma tumor. C57BL/6 mice were injected subcutaneously
with 0.75× 106 B16.F10 melanoma cells. After 14 days tumors were
excised and sections stained with the Hematoxylin/Eosin method. (A) 40×
Magnification. Blood vessel with red blood cells (red circular cells) is
shown. (B) Detail of the blood vessel depicted in (A) with the indication of
the various functional structures linking blood vessel and tumor milieu.
Yellow arrows, tumor-infiltrating leukocytes; red arrows, red blood cells;
black arrows, melanoma cells.
circumvent or dampen immunity forces, thus leading to tumor
escape from host immunosurveillance. In this scenario, the bal-
ance of immune populations endowed with effector vs. suppressive
activities at the tumor site, is a critical parameter predicting cancer
progression.
MACROPHAGES
Macrophages represent a significant portion of the tumor mass,
and they certainly operate as fundamental actors in various
types of solid cancers (Hao et al., 2012). These cells are gen-
erated from blood monocytes, which differentiate into two dis-
tinct macrophage types, schematically identified as M1 (or clas-
sically activated) and M2 (or alternatively activated) (Hao et al.,
2012). In presence of LPS/IFN-γ, monocytes differentiate in the
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M1-polarized macrophages, characterized by the production of
high levels of IL-1, IL-10, IL-23, TNF-alpha as well as CXCL10.
Instead, M2-polarized cells are generated when monocytes dif-
ferentiate in presence of IL-4, IL-10, and IL-13 (Martinez et al.,
2009; Pollard, 2009). M1- and M2-polarized macrophages are
endowed with opposite functional roles in terms of tumor suppres-
sion and immune stimulation. Indeed, whereas M1 cells, by virtue
of their ability to elicit Mydd88/TLR pathways, enhance immune
responses and restrain tumor progression, M2 macrophages
switch-off the immune system and promote tumor development
(Solinas et al., 2009). Moreover, human renal cell carcinoma
has been reported to be frequently infiltrated with M2 tumor-
associated macrophages (TAMs) promoting cancer progression.
These TAMs produce high levels of IL-10 and CCL2, and display
an elevated expression of 15-lipoxygenase-2 (15-LOX2) enzyme.
Together, these factors allow infiltrating TAMs to promote inflam-
mation, immunosuppression, and malignant progression of renal
cancer carcinoma (Daurkin et al., 2011; Eruslanov et al., 2011).
Furthermore, melanoma-infiltrating macrophages produce sig-
nificant amount of adrenomedullin, which acts in an autocrine
manner to promote their polarization toward the M2 phenotype.
The generation of M2 macrophages enforce malignant progression
and suppresses Cytotoxic T lymphocytes (CTL) activity as well as
angiogenesis (Chen et al., 2011). Likewise, M2 macrophages were
shown to play a crucial role in colon cancer progression. In a mouse
model of colorectal cancer, TAMs were shown to play an indi-
rect role by eliciting the recruitment of CCR6+TREG lymphocytes
inside the tumor mass, which then promote neoplastic progres-
sion by stimulating the secretion of CCL20 (Liu et al., 2011). In
addition to sustaining tumor progression, M2 macrophages also
promote angiogenesis. In this regard, mature F4/80+CD68+ alter-
natively activated M2 macrophages were shown to be endowed
with a strong CTL-suppressive activity in a murine BW-Sp3 T
cell lymphoma model (Van Ginderachter et al., 2006; Chen et al.,
2011).
T LYMPHOCYTES
Both preclinical and clinical studies suggest a strict correlation
between the presence of tumor-infiltrating lymphocytes (TILs)
with a favorable prognosis in a wide number of solid tumors
(Galon et al., 2006; Fridman et al., 2012; Senovilla et al., 2012),
although not all lymphocyte types are endowed with anti-tumor
activity (Vesely et al., 2011). CTL play a relevant role in the process
of tumor rejection. They are defined as CD8+ T cells produc-
ing massive amounts of IFN-γ and compounds necessary for their
cytotoxic activity, such as granzyme B and perforin. The key role of
CTL both in immunosurveillance against rising malignancies and
in contrasting the metastatic expansion has been demonstrated in
mouse models exploiting UV-induced skin cancers (Ward et al.,
1990), chemically induced papilloma (Yusuf et al., 2008), and in the
ret oncogene transgenic model of spontaneous melanoma (Eyles
et al., 2010). High frequencies of circulating CD8+ T lympho-
cytes were detected in patients with metastatic melanoma, specific
for Melan-A/MART-1, MAGE-10, and Ny-Eso-1, and CTL have
also been found infiltrating melanoma metastases (Clark et al.,
1989; Clemente et al., 1996; van Houdt et al., 2008; Fuertes et al.,
2011). On this basis, adoptive transfer of CTL is therapeutically
effective for mouse tumor models, although to a minor extent
for cancer patients (Mempel and Bauer, 2009). These T cells,
attracted by chemotactic stimuli secreted by the tumor mass,
acquire the ability to migrate toward it. CTL do not require integrin
to interact with neoplastic cells and are endowed with the ability
to shift between components of tumor mass by means of ame-
boid locomotion (Weigelin et al., 2011). Time-lapse microscopy
in a mouse melanoma model illustrated that melanoma-specific
CTL effectively traffic to the melanoma site, where they engage
contact with the B16.F10 cells via TCR/MHC-peptide interac-
tions (Weigelin et al., 2011). Subsequently, tumor cells undergo
apoptotic cell death induced by cytotoxic activity of CTL. These
forming apoptotic bodies are made available for tumor-infiltrating
dendritic cells (DC) that are thus allowed to sustain the sys-
temic tumor-specific immunosurveillance by migrating to tumor-
draining lymph nodes and other distant lymphoid organs, such
as spleen, in order to present the processed peptides to naïve T
cells. Moreover, it is also widely documented that the presence
of TILs, including CTLs, is correlated with a favorable prognosis
for several types of cancers, such as colon, breast, lung, ovar-
ian, and esophagus cancer, just to cite a few (Naito et al., 1998;
Schumacher et al., 2001; Zhang et al., 2003; Sato et al., 2005;
Alexe et al., 2007; Al-Shibli et al., 2008; Fridman et al., 2012).
The killing efficiency of target tumor cells by CTL is dependent
on several factors, such as the cytokine/chemokine patterns pro-
duced by the tumor microenvironment, the molecular plasticity
of tumor cells to evade CTL-induced killing and the strength of
TCR/MHC-peptide interactions. In this regard, melanoma cells
have been shown to down-regulate the MHC-I surface expression,
thus bypassing the interaction with CTL via TCR (Mempel and
Bauer, 2009). Of note, some reports demonstrated that induction
of co-stimulatory molecule expression in human melanoma cell
surface led to stimulation of CTL activity by Natural killer (NK)
cells (Tarazona et al., 2004).
A significant fraction of TILs is composed by the regulatory T
(TREG) cells, endowed with potent suppressive activity that coun-
teract anti-tumor effector responses and favor tumor escape and
progression. TREG cells were reported to infiltrate a wide range of
mouse and human tumors, such as melanoma, lung adenocarci-
noma, breast cancer, and gastrointestinal tumors (Quezada et al.,
2011; Wang et al., 2012b). Elevated frequencies of TREG cells in
peripheral blood and at the tumor site of cancer patients correlate
with poor prognosis and reduced survival. However the mecha-
nisms driving TREG cell expansion, accumulation, and migration
to the tumor site are currently unknown. It is likely, that factors
relevant within the tumor microenvironment, such as the pres-
ence of TGF-β and low antigen stimulation, may play a role in the
induction of TREG cells in vivo (Quezada et al., 2011). Through
the secretion of inhibitory cytokines and the expression of sur-
face markers, TREG cells inhibit the effector function of most
immune cells, including T and B cells, DC, macrophages, and
NK cells (Wang et al., 2012b). FoxP3+TREG cells within tumor
burden express elevated levels of multiple suppressive receptors
such as PD-1, CTLA-4, TIM-3, LAG-3, and GITR (Sakuishi et al.,
2010; Park et al., 2012b). The identification of these receptors
has gained interest for the development of targeted anti-tumor
strategies aimed at selectively depleting TREG cells at the tumor
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site (Menetrier-Caux et al., 2012a,b; Wang et al., 2012b). For
example, simultaneous blockade of CTLA-4 and PD-1 was shown
to reduce the frequencies of TREG cells and to increase the numbers
of effector TILs in mice bearing established B16.F10 melanoma,
improving the efficacy of tumor vaccines (Curran et al., 2010).
Similar encouraging results have been obtained with melanoma
patients, suggesting that approaches aimed at combining TREG
cell depletion-based immunotherapy with current tumor treat-
ment protocols may be promising strategies in clinical oncology
(Hodi et al., 2010). However, since PD-1 and CTLA-4 are not
uniquely expressed by TREG cells, these results may be attributable
to the blockade or re-activation of other T cell subsets (Badoual
et al., 2013). In some cases TREG cells may also contrast tumor pro-
gression. Indeed, TREG lymphocyte infiltration has been associated
with favorable prognosis in several types of solid cancers, such as
ovarian, bladder, head/neck, and colorectal tumors (Badoual et al.,
2009; Fridman et al., 2012). The mechanisms by which TREG cells
exert opposite function, depending on the tumor type, are still
under investigation, although it is plausible to hypothesize that
the phenotypical uniqueness of each cancer microenvironment
may elicit the recruitment of different TREG cell subsets (Fridman
et al., 2012).
DENDRITIC CELLS
The involvement of DC in neoplastic progression became increas-
ingly evident in the past 10 years, and has been shown by different
research groups (Preynat-Seauve et al., 2006; Shurin et al., 2006;
Fuertes et al., 2011; Galluzzi et al., 2012). Indeed, DC have been
shown to infiltrate different types of primary solid tumors. The
crucial role of these cells in the process of cancer progression
is dictated by their unique property of potent antigen present-
ing cells (APC) capable to prime naïve T lymphocytes. Several
investigations indicate that DC can be endowed with capability
to yield an active tumor-specific immune response that ultimately
reflects in tumor rejection (Preynat-Seauve et al., 2006). It has
been demonstrated that DC present tumor-specific peptides to
activated T lymphocytes during melanoma progression in tumor-
draining lymph nodes (Fuertes et al., 2011; Gerlini et al., 2012a,b).
On the other hand, the cancer immunosuppressive environment
may cause DC to develop functional impairments resulting in fail-
ure to activate T cells. (Chaux et al., 1997a,b; Vicari et al., 2002).
In this respect, DC may be viewed as a double-edged sword at
the tumor site affecting either positively or negatively the anti-
tumor response, depending on the composition of the tumor
microenvironment.
Tumor-infiltrating DC (TIDC) are present in different types
of solid cancers, including colon lesions and epitheliomas
(Michielsen et al., 2011, 2012), but the largest number of TIDC
has been found in melanoma (Furumoto et al., 2004). These
TIDC are composed by myeloid and to a lesser extent plasma-
cytoid DC (Mattei et al., 2012). The latter display an immature
phenotype in situ, but retain the ability to mature into fully compe-
tent APC following dissociation from the tumor bulk, without the
need of cytokine or bacterial product exposure (Preynat-Seauve
et al., 2006). In this regard, dying tumor cells are thought to pro-
vide maturation signals. Therefore, DC spontaneously infiltrate
melanoma and other types of solid cancers, and are potentially
endowed with the capability to process a soluble tumor-associated
antigen (Preynat-Seauve et al., 2006). These TIDC then migrate
toward draining lymph nodes in order to activate both naïve
CD4+ and CD8+ T lymphocytes (Fuertes et al., 2011; Gerlini et al.,
2012a,b). Therefore, newly generated cytotoxic CD8+ T cells may
further contribute to tumor rejection by migrating toward the
tumor site. The extent of tumor infiltration by mature DC has
been often correlated with favorable prognosis in a wide array of
clinical cancers (Cox et al., 2005; Ladanyi et al., 2007; Park et al.,
2012c). In a mouse model of melanoma, it was recently shown that
host immunodeficiency results in poor tumor infiltration by effec-
tor immune cells, such as T cells and DC, and closely associates
with melanoma progression (Mattei et al., 2012). In this model,
melanoma phenotype was shown to be shaped directly by cells of
the immune system through release of soluble factors within the
tumor microenvironment (Businaro et al., 2013).
Recent work demonstrated the crucial role of CD8α+ DC in
the natural mechanisms of cancer immunosurveillance through
response to endogenous type I IFN and induction of CTL-
mediated tumor rejection (Diamond et al., 2011; Fuertes et al.,
2011). The importance of CD8α+ DCs in anticancer response
stems in their unique ability to process and present cellular anti-
gens, in a process known as cross-presentation (den Haan et al.,
2000; Joffre et al., 2012). Cross-presentation is the ability of APC
to process exogenous antigens and present the derived peptides to
the MHC-I molecules, rather than conveying them to the classi-
cal MHC-II pathway. Cross-presentation allows APCs to present
those antigens that are not expressed by the APC itself and is
crucial for the generation of CTLs against intracellular pathogens
or tumors of non-hematopoietic origin. This occurs through a
process named cross-priming and requires optimal stimulation of
the cross-presenting DC (referred to as DC licensing) by means
of “danger signals,” such as those emitted from damaged cells, or
by inflammation (Kurts et al., 2010). In fact, in the absence of an
activation stimulus that “licenses” DC, antigen cross-presentation
does not result in cross-priming, but rather in cross-tolerance.
Of note, type I IFN have been shown to provide strong signal
for CD8α+ DCs promoting CD8+ T cell cross-priming in vivo
against antigens derived from dying tumor cells (Lorenzi et al.,
2011). However, the extent of a tumor-specific immune response
in cancer patients is a rare event. It has been hypothesized that
the reasons why a patient fails rather than succeed to give an
effective immune response toward the tumor are essentially three,
all strictly related to the composition of the cancer microenvi-
ronment: (i) immunosuppressive cytokines such as IL-10, TGF-β,
VEGF, or PGE2, interfering with the generation of immunity (Par-
doll, 2003), (ii) tumor-secreted chemokines that sequester antigen-
loaded DC, thus impeding them to migrate toward lymph nodes
(Hirao et al., 2000), (iii) inadequate ability of TIDC to capture
tumor antigen, due to poor apoptosis within cancer microenvi-
ronment (den Haan et al., 2000). A recent research of Chiba and
co-workers evidenced that the transmembrane protein TIM-3 can
act as a molecular switch by which TIDC regulate innate immune
responses against tumors. Indeed, several tumorigenic and angio-
genic factors, such as VEGF and IL-10, released by the tumor in situ
induce TIM-3 expression on TIDC surface, resulting in the sup-
pression of innate immune responses to nucleic acids by binding
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to the damage-associated molecular pattern molecule, HMGB1
(Chiba et al., 2012; Mattei and Schiavoni, 2013). These findings
have revealed a novel strategy of tumor escape from host innate
responses to nucleic acids involving TIDC and provided important
insights for therapy design involving TIM-3 targeting.
Some interesting findings suggest that tumor-specific immune
responses can also occur in certain structures distinct from sec-
ondary lymphoid organs, the so called Tertiary Lymphoid Struc-
tures. Originally discovered for their importance in autoimmunity
diseases (Takemura et al., 2001), these singular structures have sub-
sequently been identified in human lung cancers (Dieu-Nosjean
et al., 2008) and more recently in melanoma metastases (Cipponi
et al., 2012). Tertiary Lymphoid Structures exhibit a well defined
organization, with mature DC and T cells adjacent to B cell fol-
licles, thus suggesting that these structures may be a site where
tumor-specific T cell activation occurs (Fridman et al., 2012).
NATURAL KILLER CELLS
Natural killer cells are large granular lymphocytes acting by their
cytotoxic capacity and massive cytokine production. NK cells share
with macrophages the surface expression of CD16 (FcyRIII), but
are diversified from them by expression of CD7, CD56, and CD57
(Milush et al., 2009; Yasuda et al., 2011; Senovilla et al., 2012) and
by mechanisms of pathogen killing. Indeed, whereas macrophages
kill target cells by phagocytosis, NK cells mediate target cell lysis by
secretion of perforin- and granzyme B-containing granules (Pardo
et al., 2009; Afonina et al., 2010). A recent report demonstrated
that NK cells are endowed with a potent ability to secrete cal-
cium ions, and that this function allow these cells to increase their
killing ability (Schwarz et al., 2012). For their killing activity, NK
cells cover an important role in immune responses against tumors.
Another interesting function of NK cells is the so called “DC edit-
ing.” This term specifies the ability of activated NK cells to interact
with autologous DC and kill those cells that are not fully mature.
Through this process, NK cells contribute to maintain the reser-
voir of immunogenic DC by killing potentially tolerogenic DC thus
optimizing effector anti-tumor responses (Moretta, 2002; Moretta
et al., 2006; Morandi et al., 2012).
The functionality of NK cells is fundamental for contrasting
the growth and metastatic process of several types of cancers. For
example, several reports have elucidated the role of NK cells in
killing cancer cells in murine models of melanoma, colon cancer,
lung cancer, and breast cancer (Azogui et al., 1991; Pham-Nguyen
et al., 1999; Velthuis et al., 2003; Carrega et al., 2009; Frings et al.,
2011; Kim et al., 2011; Takeda et al., 2011; Vesely et al., 2011;
Roberti et al., 2012a; Srivastava et al., 2012). There are several NK
receptors, such as DNAM-1, CD155, CD16, CD69, NKp30, and
NKp46, whose surface expression is fundamental for maintaining
cancer immunosurveillance (Clausen et al., 2003; Garcia-Iglesias
et al., 2009; Lakshmikanth et al., 2009; Chan et al., 2010; Levy et al.,
2011; Pfeiffer et al., 2011; Gleason et al., 2012; Park et al., 2012a).
In this regard, some research groups investigated the intratumoral
phenotypic profile and functions of NK cells in primary human
tumors of non-small cell lung carcinoma (NSCLC) by using the
NK cell marker NKp46. The data showed that intratumoral NK
cells from these patients display a deeply altered phenotype that
strongly contributed to the NSCLC progression in these patients
(Platonova et al., 2011). These results strengthen the key role of the
cancer microenvironment and its composition, and identify NK
cells as important predictive biomarkers of neoplastic disease pro-
gression. A recent study utilizing mouse tumor models elucidated
the importance of NK cells in a vaccination strategy against lung
cancer. A survivin-based vaccination, coupled to the use of novel
form of the 4-1BBL co-stimulatory molecule as an adjuvant has
been effective in completely suppressing 3LL lung carcinoma pro-
gression. The vaccine efficacy was correlated with potent killing
responses of NK cells (Srivastava et al., 2012). Another report
highlighted the role of NK cells resident in lung tissue during
the generation of lung metastases. These findings have elucidated
that IFN-γ production by these lung-resident NK cells markedly
repressed the formation of metastases in an experimental mouse
melanoma model (Takeda et al., 2011).
Defects in NK cell number or phenotype are events that dic-
tate the fate of neoplastic diseases other than lung carcinoma.
Several investigations defined the key role of NK cell receptors
in melanoma. This is the case of DNAM-1 that interacts with the
CD155 NK-specific receptor and promote the killing of melanoma
metastasis and the generation of a “cytokine storm” that con-
tributes to the killing activity (Chan et al., 2010). Many studies
reported possible mechanisms by which melanoma cells escape
killing activity of NK cells (Balsamo et al., 2012; Pietra et al., 2012;
Wang et al., 2012a). Nevertheless, strategies aimed at promoting
and sustain the melanoma-specific killing activity of NK cells are
only at early stages or poorly effective. A recent report showed an
active role of the chemotherapeutic drug dacarbazine, largely used
for this type of neoplastic disease, in activating the expression
of NK1G receptor on NK cell surface, thus restoring the killing
activity of NK cells toward melanoma cells (Hervieu et al., 2012).
Similar encouraging approaches have been recently started for
breast cancer by using the chemotherapeutic agent Cetuximab.
This drug was shown to be effective in promoting NK cell killing
activity in high relapse rate, triple negative breast cancer patients.
Indeed, Cetuximab restored IL-2/IL-15-mediated NK cell killing
activity, thus markedly improving the outcome of these patients
(Roberti et al., 2012b). Taken together, these data strongly sup-
port a key role of NK cells in tumor progression. Indeed, when
activated, NK cells fight malignant cells inside the microenviron-
ment by direct killing as well as by contrasting the generation of
metastatic foci.
MYELOID-DERIVED SUPPRESSOR CELLS
Cancer patients and tumor-bearing experimental mice undergo
dramatic changes in their hematopoietic progeny. These modifi-
cations are mainly due to accumulation of myeloid cells, including
myeloid-derived suppressor cells (MDSC) (Serafini et al., 2004).
These cells represent a heterogeneous population, either of mono-
cytic or granulocytic origin, generated by and released from the
bone marrow in response to a wide array of stimuli (Solito et al.,
2011). MDSC are characterized by the surface expression of CD11b
and Gr-1 markers, and their common functional feature is the
repression of the effector functions of T lymphocytes and NK
cells (Serafini et al., 2004; Gabrilovich and Nagaraj, 2009). For
their potential to compromise both innate and adaptive immunity,
tumor-infiltrating MDSC critically control cancer progression.
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By using STAT6−/− mice models transplanted with 4T1 cancer
cells, Sinha et al. (2005) showed that MDSC render 4T1 mam-
mary tumors poorly immunogenic by suppressing the activation
of CD4+ and CD8+ T cells. The involvement of STAT signal-
ing in the immunosuppressive activity of MDSC in cancer has
been further evidenced in studies on human head and neck squa-
mous cell carcinoma and breast cancer, suggesting a pivotal role
of STAT3 and STAT1 pathways, respectively, for MDSC suppres-
sive activity within cancer microenvironment (Hix et al., 2013;
Vasquez-Dunddel et al., 2013). Other independent investigations
demonstrated that mice injected with 4T1 cells and subsequently
treated with cyclophosphamide displayed tumor progression and
metastatic spread despite drug treatment. Strikingly, the microen-
vironment of these tumor-bearing mice displayed a very high
number of infiltrating MDSC, and this explained the unwanted
inefficacy of chemotherapeutic cure. In addition, CD4+ and CD8+
T infiltrating cells have been shown to promote and sustain this
effect by releasing IFN-γ (Guo et al., 2012b). Because the main
property of MDSC is to contrast the immunosurveillance mech-
anisms of CD8+ and CD4+ T lymphocytes, the balance between
T cells and MDSC within the cancer microenvironment may be
a crucial cornerstone in dictating the fate of the neoplastic dis-
ease. Another recent report employing transgenic mouse models
evidences that NK cells can potentially render T cells resistant
to the suppressor activity of MDSC, and this markedly con-
tribute to the generation of an effective adoptive transfer therapy
with HER-2/neu tumor-reactive T cells and activated non-T cells,
including NK cells (Kmieciak et al., 2011). In the mouse model of
4T1 metastatic breast carcinoma, accumulation of CD11b+Gr-
1+MDSCs within the tumor tissue has been associated with
tumor progression and bone metastasis (Bunt et al., 2007; Danilin
et al., 2012) and a recent report showed that MDSC recruit-
ment is triggered by Macrophage Migration Inhibitory Factor, an
inflammatory cytokine expressed by the tumor (Simpson et al.,
2012). Likewise, marked tumor infiltration and systemic expan-
sion of CD11b+Gr-1+MDSC was found to be associated with
enhanced tumor growth and malignant phenotype in an immuno-
compromised IRF-8−/− mouse model transplanted with B16.F10
melanoma (Mattei et al., 2012). Together, these data strongly sug-
gest a close correlation between intratumoral MDSC expansion
with tumor progression and metastatic process.
The immunosuppressive functions of MDSC have been stud-
ied in several models of neoplastic diseases. It appears that
MDSC may mediate T cell suppression through cell–cell con-
tact or, alternatively, through release of soluble mediators, such
as nitric oxide, arginase-1, reactive oxygen species or suppres-
sive cytokines (e.g., IL-10) (Gabrilovich et al., 2012; Kerkar and
Restifo, 2012). Studies on B16.F10 tumor-bearing mice have
demonstrated that CCL5, a chemokine largely produced by MDSC
(Zhang et al., 2012), is required for intratumoral recruitment
of TREG cells and melanoma expansion (Schlecker et al., 2012).
Moreover, MDSCs have been shown to skew the differentiation
of CD4+ T cells into TREG (Huang et al., 2006), to induce an
M2 phenotype in macrophages and to impair DC function, sug-
gesting the existence of multiple overlapping regulatory mech-
anisms that dampen anti-tumor effector responses (Gabrilovich
et al., 2012). Finally, MDSC facilitate tumor growth by producing
pro-angiogenic factors, such as VEGF-A (Finke et al., 2011). Over-
all, MDSC exert pro-tumorigenic activity both through direct
mechanisms and by employing a myriad of immunosuppres-
sive mechanisms at the tumor site that blunt effector T cell
responses.
OTHER TUMOR-INFILTRATING IMMUNE CELL SUBSETS: γδ T AND NKT
CELLS
Besides the traditional players of anti-tumor immunity, emerg-
ing evidences suggest that other subsets of immune cells infiltrate
solid tumors and may also contribute in cancer growth control.
Among these, γδ T cells represent a small part of the lymphocyte
population that share, with all T cells, the surface expression of
TCR. Unlike αβ T cells, γδ T lymphocytes express a TCR com-
plex where CD3 is associated to a γ and δ chains (Wu et al.,
1988). These lymphocytes were originally characterized as strong
cytotoxic and IFN-γ-producing cells, thus making them pro-
totypic anti-tumor mediators. Indeed, γδ T lymphocytes have
been linked to cancer progression since the early 1990s, when an
encouraging study demonstrated their infiltration in human skin
tumors, even though no clear indications about their function was
given (Miescher et al., 1990). About a decade later, by employ-
ing mice lacking γδ T cells, Girardi et al. (2001, 2003) observed
that these mice were highly exposed to carcinogen-induced cuta-
neous tumors, thus directly demonstrating the protective role of
these cells in skin tumors. In the murine B16 melanoma model,
γδ T cells were shown to infiltrate tumor lesions soon after trans-
plantation and to provide an early source of IFN-γ (Gao et al.,
2003). Other recent examples demonstrating a protective role of
γδ T cells have been provided by two significant reports suggest-
ing the presence of γδ T lymphocytes as a favorable prognostic
factor for human breast cancer and melanoma (Kabelitz et al.,
2007; Cordova et al., 2012; Ma et al., 2012). On the other hand,
studies in mouse tumor models have demonstrated that γδ T cells
within the tumor microenvironment exert an inhibitory action
on CTL and NK cytolytic activity through production of IL-10
and TGF-β, resulting in the induction of tumor-specific immune
tolerance (Seo et al., 1999; Ke et al., 2003). Recently, by employ-
ing IL-17−/− mice two independent groups reported a subset of
IL-17-producing γδ T cells infiltrating murine tumors, although
opposite results were obtained regarding the anti-tumor activity
of these cells. Wakita et al. (2010) showed that IL-17 produced
by tumor-infiltrating γδ T cells promotes tumor progression by
inducing angiogenesis in mouse models of methylcholanthrene-
induced transplantable fibrosarcoma, skin, and colon carcinoma.
In contrast, Zitvogel’s group showed in several subcutaneous
tumor lines that early cancer infiltration by IL-17-producing γδ
T cells is required for optimal tumor colonization of IFN-γ-
producing CD8+ T cells and therapeutic efficacy of anticancer
chemotherapy, in a mechanism requiring IL-1R1 and IL-1β, thus
implying a beneficial role of IL-17-producing γδ T cells in anti-
tumor defense (Ma et al., 2011; Mattarollo et al., 2011). Thus,
the role of tumor-infiltrating γδ T cells in cancer immunosurveil-
lance is still controversial and a more detailed characterization of
γδ T cells is necessary in a wider set of preclinical tumor mod-
els that takes into account the phenotype of functional γδ T cell
subsets.
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NKT cells have also been reported to infiltrate solid tumors.
Initially identified in 1981 by Minato et al. (1981) as a population
expressing both a TCR and NK cell markers, NKT lymphocytes are
currently known as a subset of innate-like T cell that recognizes
Ag presented by CD1d (Kawano et al., 1997; Godfrey et al., 2004;
Van Kaer, 2007). The best known subset of CD1d-restricted NKT
cells, referred to as type I or invariant NKT (iNKT) cells, is charac-
terized by surface expression of defined variants of α and β chain
of the TCR, such as those encoded by vα24, vα14, vβ11, and Jα281
gene segments (Cui et al., 1997; Kawano et al., 1997; Kronenberg,
2005). These cells are conserved between humans and mice and are
implicated in many immunological processes, such as production
of massive amounts of several cytokines, both pro-inflammatory
(i.e., IL-2, IL-17, IFN-γ, and TNF-α) and regulatory (i.e., IL-4,
IL-10, and IL-13), which reflect their capacity to differently regu-
late anti-tumor responses (Swann et al., 2004; Bendelac et al., 2007;
Exley et al., 2011). Pioneering work by Cui et al. (1997) showed that
mice deficient for vα14+ iNKT cells were unable to mediate IL-12-
induced rejection of tumors and that lack of infiltration of vα14
iNKT cell in melanoma tissue resulted in cancer progression and
metastatic expansion. Subsequently, it was shown that the defec-
tive tumor immunity observed in Jα18-/- mice, selectively deficient
for iNKT cells, against methylcholanthrene-induced sarcomas and
melanoma lung metastasis could be restored by adoptive trans-
fer of IFN-γ-producing iNKT cells from WT donor mice (Crowe
et al., 2005). iNKT cells can be recruited to the tumor by inducing
local expression of chemokines, such as CCL21 or CXCL16 (Turn-
quist et al., 2007; Kee et al., 2013) and be functionally activated
by the alpha-galactosylceramide producing beneficial effects in a
variety of solid tumors (Nakagawa et al., 2000; Osada et al., 2004;
Nagato et al., 2012). iNKT cell infiltration in primary tumors has
been correlated with a favorable outcome in patients with colorec-
tal carcinoma (Tachibana et al., 2005), neuroblastoma (Metelitsa
et al., 2004), and hepatocellular carcinoma (Guo et al., 2012a).
On the other hand, iNKT cells have also been described to sup-
press tumor immunosurveillance based on their production of
Th2 cytokines (Terabe et al., 2000; Exley et al., 2011). It has been
proposed that the instauration of a protective or suppressive anti-
tumoral activity of iNKT cells may depend on the cytokine pattern
of the cancer microenvironment and on the action of suppres-
sive populations, such as MDSC and TAMs (Smyth and Godfrey,
2000; Terabe et al., 2003; Liu et al., 2012). Other, less characterized,
CD1d-reactive NKT cells that have non-V24 (V14) invariant or
variable TCR (type II NKT) as well as some non-CD1d-reactive
NKT cell subsets that share with the NK cells the surface expres-
sion of a number of NK-associated receptors, such as CD161
(NK1.1), CD16, and CD56, have been described (Godfrey et al.,
2004; Bendelac et al., 2007; Metelitsa, 2011). Several reports have
demonstrated that type II NKT cells can mediate suppression of
tumor immunosurveillance in multiple mouse tumor models by
counteracting iNKT cell activities (Terabe et al., 2005; Berzofsky
and Terabe, 2008; Izhak et al., 2013). However, these type II NKT
cells have not been characterized in tumor infiltrates yet, indi-
cating the need of further exploration for possible relevance of
these cells in the local control of tumor growth and metastatic
process.
CANCER STEM CELLS IN THE TUMOR MICROENVIRONMENT:
RESIDENT OR NON-RESIDENT?
In the recent years, many reports proposed the definition of a new
hierarchical model of cell organization, based on the discovery
of a CSC. In this new model these tissue-specific, resident CSC
acquire and retain the features of self-renewal, multilineage, dif-
ferentiation, and tumor initiation both in vitro and in vivo (Boral
and Nie, 2012). Importantly, CSC is the unique cell type of the
tumor microenvironment able to initiate and maintain the for-
mation of the environment itself and allow cancer progression.
On the other hand, CSC are also equipped with the capability
to colonize distant sites (Sengupta and Cancelas, 2010). Thus, in
the context of solid tumors, CSC belong to both resident and
non-resident compartments (Table 1). Nevertheless, despite a
constantly increasing number of reports seem to stress a crucial
role for CSC in carcinogenesis, there is so far no direct evidence
that CSC are phenotypically tumorigenic cells significantly differ-
ent from non-tumorigenic ones. All these reports postulate the
Cancer Resident Cell (CRC) assumption on the simple obser-
vation that carcinogenesis is the result of cumulative mutations
that develop during cancer progression. Genetic and epigenetic
forces seem to work as main actors in this scenario. Hence, each
mutated cell generates an independent, self-renewing clone of
CRC, that will take part to the tumor mass contributing to its
development (Gupta et al., 2009). As a consequence, it appears that
the tumor microenvironment may theoretically be composed of
an epigenetically heterogeneous population of CSC, representing
self-renewing “stem clones” by which each tumor cell originates
(Figure 2). CSC were first discovered in hematologic malignancies
as the Acute Myeloid Leukemia tumor initiating cell, a primitive
CD34+ hematopoietic cell susceptible to leukemic transforma-
tion (Bonnet and Dick, 1997), and successively identified in solid
tumors, such as melanoma (Visvader and Lindeman, 2008; Shack-
leton and Quintana, 2010). The presence of melanoma CSC was
discovered by using the immunocompromised mice NOD/SCID
xenotransplanted with single human melanoma cell obtained
from cancer biopsies (Quintana et al., 2008). Although the results
demonstrated, for the first time in solid tumors, the existence of
a single cell potentially endowed with the ability to generate a
true tumor mass, no information was given about surface markers
distinguishing the CSC phenotype (Quintana et al., 2008).
It has been recently elucidated that CSC can directly or indi-
rectly interact with several immune cell populations, both in vitro
and within the tumor microenvironment. These interactions are
thought to influence the outcome of cancer progression. An inter-
esting example comes from TREG cells, endowed with the ability
to produce and release TGF-β in the cancer microenvironment.
TGF-β signaling and TGF-β-induced Endothelial-Mesenchymal
Transition (EMT) are viewed as key orchestrators in the reg-
ulation of CSCs and TREG participate in this process through
producing TGF-β (Yu et al., 2012). Strikingly, a relevant research
demonstrates that TGF-β and leukemia inhibitory factor (LIF)
are responsible for the formation of neurospheres and the self-
renewal ability of glioma-initiating cell (GICs) and that the effect
of TGF-β is dependent on induction of LIF and JAK-STAT path-
way (Penuelas et al., 2009). Moreover, TREG cells, in concert with
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FIGURE 2 | Role of the cancer stem cells in the development of the
tumor microenvironment. Cancer progression is generated and
sustained by several factors, such as epigenetic forces, somatic
mutations, and EMT. On the other hand, these events lead to the
generation of distinct cancer stem cell clones inside the cancer moiety,
and enrich the cancer stem cell niche. During the late stages of tumor
progression these stem cell clones sustain the cancer expansion with
their self-renewal ability. Thus, the cancer stem cell niche can also be
regarded as a reservoir of self-sustaining cells for the tumor
microenvironment.
CSC, could affect the angiogenesis and VEGF-A level at the tumor
site, especially when its microenvironment is hypoxic. This elic-
its vascularization extent and thus facilitates angiogenesis itself,
which in turn allow CSC proliferation and maintenance inside the
cancer microenvironment (Facciabene et al., 2011; Yu et al., 2012).
Effector T lymphocytes exert opposite effects to those observed
with TREG cells by induction of CTL capable to repress the expan-
sion of CSC in ovarian cancer. This effect has been exploited
to direct CTL to effectively killing ovarian CSC (OCSC) in a
chemotherapeutic context. In this report, cell chimeras generated
by fusion of DC and OCSC to specifically target the OCSC subpop-
ulations were shown to activate T cells to express elevated levels
of IFN-γ with potent killing activity of CD44+ OVCA cells (Weng
et al., 2011). The NK have also been reported to affect CSC activi-
ties. It has been demonstrated that NK cells are endowed with the
ability to kill human melanoma stem cells with high levels of the
CD133 marker (Pietra et al., 2009). In this study, the authors were
able to show that CD133-positive melanoma CSC, isolated from a
FO-1 melanoma cell line by cell enrichment, were effectively killed
by activated NK cells. Moreover, myeloid-derived cells such as DC
may be effective in targeting Glioma stem cells (GSC), leading to
the complete eradication of this malignant primary brain tumor (Ji
et al., 2013). Here, the authors prepared a tumor vaccine by loading
DC with U251 human GSC lysates and showed that these antigen-
loaded DC are endowed with the ability to induce tumor-specific
CTLs that killed glioma cells in vitro. TAM have also been shown
to modulate the tumorigenic and angiogenic potential of CSC
within tumor transplanted mouse model (Jinushi et al., 2011). A
recent study reported that inhibition of TAM by targeting either
the myeloid cell receptors CSF1R or CCR2 decreases the num-
ber of tumor initiating cells in pancreatic tumors (Mitchem et al.,
2012). Thus, inhibiting macrophages function can lead to cancer
eradication via diminishing the presence of CSC inside the tumor
microenvironment. Finally, little is known about the interactions
between MDSC and CSC. However, since MDSC are pivotal for
the generation and maintenance of an aggressive cancer microen-
vironment, it has been recently hypothesized that these cells may
also act as a distinct tumor niche whose main function is the main-
tenance of self-renewal ability of the niche itself, thus functionally
resembling to CSC (Ye et al., 2010).
Overall, CSC are an important and integrated component of
the cancer microenvironment. Through their self-renewal abil-
ity, CSC also function by tightly interacting with the other resi-
dent and non-resident component of the environment, thus cru-
cially controlling cancer progression and maintaining the tumor
mass.
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Table 2 | Immune cells infiltrating the tumor microenvironment and their role in tumor progression.
Cell type Representative
infiltrating population
Outcome Main features of infiltrating cells inside the
tumor microenvironment
Macrophages M1 TR Activation of immune responses by MyDD88/TLR pathways
M2 TP Promotion of angiogenesis; suppression of CTL function;
recruitment of CCR6+TREG; positive modulation of the
tumorigenic and angiogenic potential of CSC
T lymphocytes CTL TR Specific tumor cell killing activity
TREG TP/TR TP: functional suppression of CTL, DC, NK cells, and
macrophages.
TR: correlation with good prognosis in some solid tumors,
hypothetically due to lacking of suppressor activity and other
unidentified activities
γδT cells TP/TR TP: inhibition of CTL and NK cell activity; promotion of
angiogenesis
TR: cytotoxic activity, IFN-γ production
Dendritic cells CD8α+ DC TR Processing and presentation of soluble tumor-associated
antigens; Type I IFN-dependent CD8+ T cell cross-priming
against antigens released from dying tumor cells
Plasmacytoid DC TR Processing and presentation of soluble tumor associated
antigens
TIM-3+ DC TP Suppression of HMGB1-dependent innate immune
responses
NK cells NKp46+ TR Specific tumor cell killing activity by secretion of perforin
and granzyme B-containing granules as well as release of





NKT cells NK receptors TP/TR TP: CD1d-restricted cytotoxic activity; IFN-γ production; APC
stimulationTCR-α chain variants




CD11b+Gr-1+ TP Repression of the effector function of T lymphocytes and NK
cells; highly present in late stages of tumor progression;
promotion of TREG functions; promotion and sustainment of
angiogenesis; present in elevated number in highly
aggressive microenvironments
Cancer stem cells CD34+ CD133+ TP Self-renewal function; tumor initiating activity; promotion
and sustainment of angiogenesis; tumor resistance;
sustainment of the tumor mass
TP, tumor progression; TR, tumor regression.
NEW APPROACHES TO STUDY THE CANCER
MICROENVIRONMENT
Exploiting complex experimental systems such as confocal
microscopy, electron microscopy or two photon microscopy allow
oncoimmunologists to “capture” suggestive images finely repre-
senting the cell–cell interactions occurring in biological systems.
However, the existent traditional experimental protocols do not
allow monitoring and visualizing in real time the interactions
between immune and tumor cells occurring inside the cancer
microenvironment.
Over the past decade, innovative approaches devoted to the
reproduction of biological systems at the microscale, such as
microfluidic platforms, have gained interest for the study of one or
multiple biological systems. The first pioneering studies on biosen-
sors performed in 1990s to investigate on the kinetics between
the antigen-antibody interactions gave a decisive boost on this
research area (Karlsson et al., 1991). This subsequently led to the
engineering of microfluidic systems to investigate on biological
fluids (Wilding et al., 1994) and, subsequently, on cell systems
(Li and Harrison, 1997). Since 2004 microfluidic approaches have
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been employed to investigate on cells belonging to immune sys-
tem to investigate migratory and morphological parameters in
response to external stimuli (Lin et al., 2004; Wong et al., 2008; But-
ler et al., 2010; Li et al., 2011). In addition, a magnetic microfluidic
chip has been developed to isolate circulating human colon cancer
cells (Choi et al., 2010; Xia et al., 2011) or to study chemoattrac-
tant properties of tumor cells (Goerge et al., 2007). Other studies
have exploited cell-on-chip based platforms to investigate the sus-
ceptibility of tumor cells to chemotherapeutic drugs (Liu et al.,
2007; Siyan et al., 2009; Kim et al., 2012). Thus, the extreme versa-
tility and the high customization potential of microfluidic-based
technologies have open promising perspectives on the use of these
approaches for cancer biology studies (Wlodkowic and Cooper,
2010; Wlodkowic and Darzynkiewicz, 2010).
In this context, the reconstitution on-chip of the cancer
microenvironment may allow to elucidate the fine mechanisms
that mechanically regulate the interactions of tumor cells with
other resident and non-resident components, such as the immune
cells, as well as the mechanisms driving the differentiation and
metastatic mobilization. Recently, a simple cell-on-chip approach
has been developed to investigate the crosstalk between two com-
plex biological systems, such as immune system and cancer (Busi-
naro et al., 2013). By using a microfluidic platform consisting
of three wide, parallel chambers interconnected via an array of
short and narrow capillary migration channels, Businaro and Col-
leagues were able to visualize and follow, “under the microscope,”
the interactions between the immune and cancer cells. The goal
of the study was to investigate the role of IRF-8 immune defi-
ciency on immune response to melanoma. Thus, splenic immune
cells from IRF-8−/− mice or WT controls were allowed to interact
with B16.F10 melanoma cells into the microfluidic structure. The
results evidenced a marked inability of IRF-8−/− immune cells to
migrate toward and interact with melanoma cells with respect to
WT cells. In turn, melanoma cells acquired a more invasive behav-
ior in the presence of immunodeficient cells, indicating a crosstalk
between cancer and immune cells shaping the phenotype of tumor
cells. Notably, these results are fully compatible with the findings
reported in vivo by the same group, suggesting the reliability of
the system (Mattei et al., 2012). The observations reported in this
study are difficult to obtain with the standard well plate culture
experiments, but are easily available with the use of a microflu-
idic platform. Thus, customized microfluidic platform may be
potentially helpful to study, follow, and mimic the plethora of
events occurring inside the cancer microenvironment. In addition
they can also be utilized as helpful tools in preclinical and clinical
investigations.
CONCLUDING REMARKS
Immune cell infiltration within the tumor microenvironment is
a crucial requisite for a successful and prompt eradication of the
primary tumor itself. Each cell type herein supports the main-
tenance of the microenvironment itself both functionally and
biochemically, by orchestrating cell–cell interactions and secret-
ing a plethora of chemokines and cytokines. This leads to a fine
tuning of the timing and modality of immune response, as well
as to an appropriate modulation and maintenance of angiogenic
processes. The final effect of such a strictly related phenomena may
either be the generation of a tumor-specific immune response or
tumor escape (Table 2).
Thus, a better knowledge of the crosstalk between cancer cells
and immune system cells occurring inside the tumor bed is of
interest for further improving cancer therapies. In this respect,
great benefit for anticancer research and clinical practice may arise
from exploiting new versatile biotechnologies, such as microfluidic
cell-on-chip platforms.
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